What is Zimvie In share price today?

Zimvie In (ZIMV) share price today is {{live_price}}.

Can Indians buy Zimvie In shares?

Yes, Indians can invest in the Zimvie In (ZIMV) from India. With INDmoney, you can buy Zimvie In at 0 brokerage. The step-by-step process is as follows: Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes) Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates. Once funds are transferred successfully, you can buy Zimvie In at zero transaction cost.

How can I buy Zimvie In shares from India?

It is very easy to buy Zimvie In from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Zimvie In be purchased?

Yes, you can buy fractional shares of Zimvie In with INDmoney app.

What are the documents required to start investing in Zimvie In stocks?

To start investing in Zimvie In, You will need the following documents: Proof of Identification (PAN, Aadhaar etc) Proof of address (Aadhaar, Voter ID etc) These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Zimvie In

Today’s highest price of Zimvie In (ZIMV) is {{1_rba_end}}. Today’s lowest price of Zimvie In (ZIMV) is {{1_rba_st}}.

What is today's market capitalisation of Zimvie In

Today's market capitalisation of Zimvie In ZIMV is 428.5M

What is the 52 Week High and Low Range of Zimvie In

52 Week High {{rba_end}} 52 Week Low {{rba_st}}

How much percentage Zimvie In is down from its 52 Week High?

Zimvie In (ZIMV) share price is {{live_price}}. It is down by {{w52lu}}% from its 52 Week High price of {{rba_end}}.

How much percentage Zimvie In is up from its 52 Week low?

Zimvie In (ZIMV) share price is {{live_price}}. It is up by {{w52hd}}% from its 52 Week Low price of {{rba_st}}.

What are the historical returns of Zimvie In?

1 Month Returns {{1mr}}% 3 Months Returns {{3mr}}% 1 Year Returns {{1yr}}% 5 Years Returns {{5yr}}%

Who is the Chief Executive Officer (CEO) of Zimvie In

Mr. Vafa Jamali is the current Chief Executive Officer (CEO) of Zimvie In.

Home>
US Stocks>
Zimvie In

Zimvie In (ZIMV)

$15.76

+0.22

(+1.42%)▲

Market is closed - opens 7 PM, 10 Oct 2024

Performance

$15.44
$15.99
$15.76
2.03%
Downside
Day's Volatility :3.44%
Upside
1.44%
$6.52
$22.40
$15.76
58.63%
Downside
52 Weeks Volatility :70.89%
Upside
29.64%

Returns

Period	Zimvie In	Sector (Health Care)	Index (Russel 2000)
3 Months	-14.33%	4.7%	0.0%
6 Months	-8.53%	5.9%	0.0%
1 Year	72.86%	16.3%	0.0%
3 Years	-39.13%	19.6%	-20.8%

Highlights

Market Capitalization	428.5M
Book Value	$14.29
Earnings Per Share (EPS)	-2.04
Wall Street Target Price	20.37

Profit Margin	-77.58%
Operating Margin TTM	-1.43%

Return On Assets TTM	-0.36%
Return On Equity TTM	-9.78%

Revenue TTM	453.4M
Revenue Per Share TTM	16.85
Quarterly Revenue Growth YOY	-1.5%
Gross Profit TTM	613.1M
EBITDA	-19.9M
Diluted Eps TTM	-2.04
Quarterly Earnings Growth YOY	0.0

EPS Estimate Current Year	0.54
EPS Estimate Next Year	0.65
EPS Estimate Current Quarter	0.17
EPS Estimate Next Quarter	0.12

Analyst Recommendation

Sell

0%Buy

42%Hold

57%Sell

Based on 7 Wall street analysts offering stock ratings for Zimvie In(by analysts ranked 0 to 5 stars)

Based on 7 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast

What analysts predicted

Upside of 29.25%

Current $15.76

Target $20.37

Company Financials

	FY18	Y/Y Change
Revenue	1.1B	-
Net Income	-460.4M	-
Net Profit Margin	-41.89%	-

	FY19	Y/Y Change
Revenue	1.1B	↓ 3.97%
Net Income	-27.9M	↓ 93.94%
Net Profit Margin	-2.64%	↑ 39.25%

	FY20	Y/Y Change
Revenue	912.4M	↓ 13.56%
Net Income	-179.0M	↑ 541.58%
Net Profit Margin	-19.62%	↓ 16.98%

	FY21	Y/Y Change
Revenue	1.0B	↑ 11.2%
Net Income	-95.3M	↓ 46.76%
Net Profit Margin	-9.39%	↑ 10.23%

	FY22	Y/Y Change
Revenue	913.9M	↓ 9.93%
Net Income	-63.9M	↓ 32.97%
Net Profit Margin	-6.99%	↑ 2.4%

	FY23	Y/Y Change
Revenue	457.4M	↓ 49.95%
Net Income	-393.3M	↑ 515.65%
Net Profit Margin	-85.98%	↓ 78.99%

	Q1 FY23	Q/Q Change
Revenue	225.4M	↓ 1.61%
Net Income	-30.0M	↓ 1.24%
Net Profit Margin	-13.29%	↓ 0.05%

	Q2 FY23	Q/Q Change
Revenue	224.9M	↓ 0.24%
Net Income	-23.4M	↓ 22.01%
Net Profit Margin	-10.39%	↑ 2.9%

	Q3 FY23	Q/Q Change
Revenue	202.9M	↓ 9.79%
Net Income	-5.1M	↓ 78.23%
Net Profit Margin	-2.51%	↑ 7.88%

	Q4 FY23	Q/Q Change
Revenue	113.1M	↓ 44.27%
Net Income	-334.9M	↑ 6479.92%
Net Profit Margin	-296.16%	↓ 293.65%

	Q1 FY24	Q/Q Change
Revenue	118.2M	↑ 4.54%
Net Income	-7.8M	↓ 97.68%
Net Profit Margin	-6.57%	↑ 289.59%

	Q2 FY24	Q/Q Change
Revenue	116.8M	↓ 1.17%
Net Income	-4.0M	↓ 48.28%
Net Profit Margin	-3.44%	↑ 3.13%

	FY19	Y/Y Change
Total Assets	2.1B	-
Total Liabilities	442.3M	-

	FY20	Y/Y Change
Total Assets	1.9B	↓ 7.64%
Total Liabilities	458.7M	↑ 3.71%

	FY21	Y/Y Change
Total Assets	1.8B	↓ 6.28%
Total Liabilities	375.3M	↓ 18.18%

	FY22	Y/Y Change
Total Assets	1.6B	↓ 10.11%
Total Liabilities	883.5M	↑ 135.4%

	FY23	Y/Y Change
Total Assets	1.2B	↓ 26.6%
Total Liabilities	795.9M	↓ 9.92%

	Q1 FY23	Q/Q Change
Total Assets	1.6B	↓ 3.29%
Total Liabilities	844.5M	↓ 4.41%

	Q2 FY23	Q/Q Change
Total Assets	1.6B	↓ 1.73%
Total Liabilities	832.7M	↓ 1.39%

	Q3 FY23	Q/Q Change
Total Assets	1.5B	↓ 3.37%
Total Liabilities	797.7M	↓ 4.2%

	Q4 FY23	Q/Q Change
Total Assets	1.2B	↓ 20.07%
Total Liabilities	795.9M	↓ 0.23%

	Q1 FY24	Q/Q Change
Total Assets	1.2B	↓ 2.8%
Total Liabilities	783.3M	↓ 1.58%

	Q2 FY24	Q/Q Change
Total Assets	789.8M	↓ 32.59%
Total Liabilities	395.7M	↓ 49.48%

	FY18	Y/Y Change
Operating Cash Flow	162.0M	-
Investing Cash Flow	-50.3M	-
Financing Cash Flow	-97.3M	-

	FY19	Y/Y Change
Operating Cash Flow	119.2M	↓ 26.42%
Investing Cash Flow	-84.6M	↑ 68.19%
Financing Cash Flow	-43.7M	↓ 55.09%

	FY20	Y/Y Change
Operating Cash Flow	86.0M	↓ 27.85%
Investing Cash Flow	-49.5M	↓ 41.49%
Financing Cash Flow	-46.5M	↑ 6.41%

	FY21	Y/Y Change
Operating Cash Flow	64.3M	↓ 25.23%
Investing Cash Flow	-60.3M	↑ 21.82%
Financing Cash Flow	72.3M	↓ 255.48%

	FY22	Y/Y Change
Operating Cash Flow	24.6M	↓ 61.7%
Investing Cash Flow	-28.7M	↓ 52.47%
Financing Cash Flow	-1.3M	↓ 101.81%

	Q1 FY23	Q/Q Change
Operating Cash Flow	-7.2M	↓ 19.15%
Investing Cash Flow	-5.8M	↑ 4.91%
Financing Cash Flow	-10.9M	↓ 33.78%

	Q2 FY23	Q/Q Change
Operating Cash Flow	256.0K	↓ 103.56%
Investing Cash Flow	-1.3M	↓ 78.28%
Financing Cash Flow	1.2M	↓ 110.65%

Technicals Summary

Sell

Neutral

Buy

Zimvie In is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Zimvie In	-4.72%	-8.53%	72.86%	-39.13%	-39.13%
Stryker Corporation	-3.31%	-0.03%	31.48%	35.58%	66.35%
Boston Scientific Corp.	3.86%	25.02%	63.82%	103.7%	122.33%
Edwards Lifesciences Corp.	4.31%	-26.34%	-5.98%	-36.82%	-8.54%
Abbott Laboratories	-1.55%	1.95%	18.47%	-1.93%	44.19%
Medtronic Plc	-2.74%	5.18%	17.32%	-28.65%	-17.43%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Zimvie In	NA	NA	NA	0.54	-0.1	0.0	NA	14.29
Stryker Corporation	39.06	39.06	2.54	12.01	0.19	0.07	0.01	51.86
Boston Scientific Corp.	69.79	69.79	2.11	2.41	0.09	0.05	NA	13.85
Edwards Lifesciences Corp.	26.98	26.98	3.41	2.62	0.22	0.12	NA	12.35
Abbott Laboratories	36.16	36.16	4.18	4.66	0.14	0.06	0.02	22.6
Medtronic Plc	29.68	29.68	1.63	5.2	0.08	0.04	0.03	37.39

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Zimvie In	Sell	$428.5M	-39.13%	NA	-77.58%
Stryker Corporation	Buy	$133.7B	66.35%	39.06	16.12%
Boston Scientific Corp.	Buy	$126.4B	122.33%	69.79	12.0%
Edwards Lifesciences Corp.	Buy	$41.3B	-8.54%	26.98	23.74%
Abbott Laboratories	Buy	$199.4B	44.19%	36.16	13.65%
Medtronic Plc	Buy	$113.0B	-17.43%	29.68	12.06%

Insights on Zimvie In

Decreasing Revenue
Revenue is down for the last 2 quarters, 118.19M → 116.81M (in $), with an average decrease of 1.2% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -334.85M → -4.01M (in $), with an average increase of 2154.0% per quarter